

Genevieve M Boland

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5995249/publications.pdf>

Version: 2024-02-01

108
papers

10,534
citations

76294

40
h-index

40954

93
g-index

116
all docs

116
docs citations

116
times ranked

17153
citing authors

#	ARTICLE	IF	CITATIONS
1	Incorporating Well-Being into Mentorship Meetings: A Case Demonstration at Massachusetts General Hospital Department of Surgery a Harvard Medical School Affiliate. <i>American Journal of Lifestyle Medicine</i> , 2023, 17, 213-215.	0.8	3
2	Harnessing the Potential of Combination Immunotherapy and Oncolytic Virotherapy for Solid Tumors. <i>Annals of Surgical Oncology</i> , 2022, 29, 762-763.	0.7	1
3	PIVOT-12: a phase III study of adjuvant bempedegalesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence. <i>Future Oncology</i> , 2022, 18, 903-913.	1.1	7
4	Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). <i>Annals of Surgical Oncology</i> , 2022, 29, 3694-3708.	0.7	21
5	Association between serum lactate dehydrogenase and cutaneous immune-related adverse events among patients on immune checkpoint inhibitors for advanced melanoma. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 1147-1149.	0.6	4
6	Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma. <i>Cell Reports Medicine</i> , 2022, 3, 100500.	3.3	13
7	Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study. <i>British Journal of Dermatology</i> , 2022, 187, 401-410.	1.4	21
8	STAG2 regulates interferon signaling in melanoma via enhancer loop reprogramming. <i>Nature Communications</i> , 2022, 13, 1859.	5.8	21
9	Landscape of helper and regulatory antitumour CD4+ T cells in melanoma. <i>Nature</i> , 2022, 605, 532-538.	13.7	70
10	MO344: Effect of Cancer Stage on Adverse Kidney Outcomes in Patients With Advanced Melanoma Treated With Immune Checkpoint Inhibitors. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.4	0
11	Glycoproteomics as a powerful liquid biopsy-based predictor of checkpoint inhibitor treatment benefit in metastatic malignant melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 9545-9545.	0.8	4
12	Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition. <i>Cancer Immunology Research</i> , 2022, 10, 996-1012.	1.6	18
13	Abstract 1270: Glycoproteomics-based liquid biopsy informs optimal checkpoint-inhibitor drug choice. <i>Cancer Research</i> , 2022, 82, 1270-1270.	0.4	0
14	Abstract 2030: A single-cell spatially resolved map of colorectal cancer identifies novel spatial relationships between cancer cells and the microenvironment. <i>Cancer Research</i> , 2022, 82, 2030-2030.	0.4	3
15	Abstract 3610: In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer. <i>Cancer Research</i> , 2022, 82, 3610-3610.	0.4	0
16	Spatial transcriptomics characterization of hepatocellular carcinoma using Molecular Cartography. <i>Journal of Clinical Oncology</i> , 2022, 40, e16110-e16110.	0.8	1
17	Single-cell profiling of human heart and blood in immune checkpoint inhibitor-associated myocarditis. <i>Journal of Clinical Oncology</i> , 2022, 40, 2507-2507.	0.8	1
18	Massively parallel single-cell mitochondrial DNA genotyping and chromatin profiling. <i>Nature Biotechnology</i> , 2021, 39, 451-461.	9.4	150

#	ARTICLE	IF	CITATIONS
19	The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis. <i>Cancer Discovery</i> , 2021, 11, 678-695.	7.7	114
20	Adjuvant Radiation Therapy for Clinical Stage III Melanoma in the Modern Therapeutic Era. <i>Annals of Surgical Oncology</i> , 2021, 28, 3512-3521.	0.7	8
21	Surgical delay and mortality for primary cutaneous melanoma. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1089-1091.	0.6	8
22	Type 2 immunity is maintained during cancer-associated adipose tissue wasting. <i>Immunotherapy Advances</i> , 2021, 1, ltab011.	1.2	13
23	Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	54
24	Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort. , 2021, 9, e002092.		7
25	Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5586-5594.	3.2	178
26	Low expression of the PPAR γ -regulated gene thioredoxin-interacting protein accompanies human melanoma progression and promotes experimental lung metastases. <i>Scientific Reports</i> , 2021, 11, 7847.	1.6	12
27	Rapid corticosteroid taper versus standard of care for immune checkpoint inhibitor induced nephritis: a single-center retrospective cohort study. , 2021, 9, e002292.		25
28	Temporal Trends in Inpatient Oncology Census Before and During the COVID-19 Pandemic and Rates of Nosocomial COVID-19 Among Patients with Cancer at a Large Academic Center. <i>Oncologist</i> , 2021, 26, e1427-e1433.	1.9	11
29	Characterizing the tumor and immune landscape of melanoma patients treated with combined checkpoint blockade and MAPK targeted therapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9522-9522.	0.8	1
30	Evolution of delayed resistance to immunotherapy in a melanoma responder. <i>Nature Medicine</i> , 2021, 27, 985-992.	15.2	67
31	Discrepancies in response and immune-related adverse events (irAE) of anti-PD-1 monotherapy between races and primary sites in patients (pts) with advanced nonacral cutaneous melanoma (NACM).. <i>Journal of Clinical Oncology</i> , 2021, 39, 9530-9530.	0.8	1
32	Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID-19. <i>Oncologist</i> , 2021, 26, 685-693.	1.9	3
33	Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. <i>Nature</i> , 2021, 596, 119-125.	13.7	239
34	Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 5993-6000.	3.2	70
35	Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance. <i>Cancer Research</i> , 2021, 81, 5230-5241.	0.4	9
36	Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. , 2021, 9, e002886.		9

#	ARTICLE	IF	CITATIONS
37	Absolute quantification of tumor antigens using embedded MHC-I isotopologue calibrants. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	25
38	Spatially organized multicellular immune hubs in human colorectal cancer. Cell, 2021, 184, 4734-4752.e20.	13.5	256
39	NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 364-376.	2.3	167
40	Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma. Nature Communications, 2021, 12, 6023.	5.8	21
41	641â€¦Spatially organized multicellular immune hubs in MMRd and MMRp colorectal cancer. , 2021, 9, A670-A670.		0
42	920â€¦A single-cell spatially resolved MERFISH map of the colorectal tumor immune microenvironment. , 2021, 9, A965-A965.		2
43	Differential pre-malignant programs and microenvironment chart distinct paths to malignancy in human colorectal polyps. Cell, 2021, 184, 6262-6280.e26.	13.5	125
44	Successful Mentor-Mentee Relationship. Journal of Surgical Research, 2020, 247, 332-334.	0.8	11
45	Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. , 2020, 8, e001583.		15
46	Plasma-derived extracellular vesicle analysis and deconvolution enable prediction and tracking of melanoma checkpoint blockade outcome. Science Advances, 2020, 6, .	4.7	37
47	Reversal of pre-existing NGFR-driven tumor and immune therapy resistance. Nature Communications, 2020, 11, 3946.	5.8	71
48	The Human and Mouse Enteric Nervous System at Single-Cell Resolution. Cell, 2020, 182, 1606-1622.e23.	13.5	287
49	Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma. Clinical Cancer Research, 2020, 26, 6039-6050.	3.2	24
50	Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nature Medicine, 2020, 26, 1114-1124.	15.2	216
51	CRISPR Screens Identify Essential Cell Growth Mediators in BRAF Inhibitor-resistant Melanoma. Genomics, Proteomics and Bioinformatics, 2020, 18, 26-40.	3.0	14
52	Mixed Response to Immunotherapy in Patients with Metastatic Melanoma. Annals of Surgical Oncology, 2020, 27, 3488-3497.	0.7	24
53	ASO Author Reflections: Mixed Response in Metastatic Melanoma Patients Treated with Immunotherapy. Annals of Surgical Oncology, 2020, 27, 3498-3499.	0.7	0
54	ASO Author Reflections: Adjuvant Treatment of Melanoma in the Modern Era. Annals of Surgical Oncology, 2020, 27, 5137-5138.	0.7	0

#	ARTICLE	IF	CITATIONS
55	Integration of Digital Pathologic and Transcriptomic Analyses Connects Tumor-Infiltrating Lymphocyte Spatial Density With Clinical Response to BRAF Inhibitors. <i>Frontiers in Oncology</i> , 2020, 10, 757.	1.3	11
56	Targeting the cyclin-dependent kinase 5 in metastatic melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 8001-8012.	3.3	21
57	Use of immunotherapy and surgery for stage IV melanoma. <i>Cancer</i> , 2020, 126, 2614-2624.	2.0	14
58	Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy. <i>Cell</i> , 2020, 182, 655-671.e22.	13.5	259
59	Tracking early response to immunotherapy. <i>Nature Cancer</i> , 2020, 1, 160-162.	5.7	9
60	Adjuvant Therapy Failure Patterns in the Modern Era of Melanoma Management. <i>Annals of Surgical Oncology</i> , 2020, 27, 5128-5136.	0.7	13
61	NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 120-131.	2.3	11
62	Investigating the tumor immune infiltrate for populations that predict immune-related adverse events (irAEs) in patients receiving PD-1 inhibitors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3116-3116.	0.8	0
63	The use of plasma proteomic markers to understand the biology of immunotherapy response.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10062-10062.	0.8	0
64	PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. <i>Nature Immunology</i> , 2019, 20, 1231-1243.	7.0	217
65	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , The, 2019, 20, e378-e389.	5.1	155
66	The Patient Speaks: Importance of Patient Perspectives in Clinical Decision-Making. <i>Annals of Surgical Oncology</i> , 2019, 26, 2665-2666.	0.7	2
67	Oncolytic Immunotherapy. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 419-430.	0.6	8
68	A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of <i>BRAF</i> -mutated Melanoma to MAPK Inhibitors. <i>Clinical Cancer Research</i> , 2019, 25, 6852-6867.	3.2	74
69	Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy. <i>Immunity</i> , 2019, 50, 1498-1512.e5.	6.6	406
70	Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 897-905.	2.0	38
71	Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy. <i>Molecular Systems Biology</i> , 2019, 15, e8323.	3.2	25
72	Lineage Tracing in Humans Enabled by Mitochondrial Mutations and Single-Cell Genomics. <i>Cell</i> , 2019, 176, 1325-1339.e22.	13.5	345

#	ARTICLE	IF	CITATIONS
73	ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma. <i>Cancer Discovery</i> , 2019, 9, 396-415.	7.7	71
74	The Effectiveness of Checkpoint Inhibitor Combinations and Administration Timing Can Be Measured by Granzyme B PET Imaging. <i>Clinical Cancer Research</i> , 2019, 25, 1196-1205.	3.2	85
75	A plasma-only integrated genomic and epigenomic circulating tumor DNA (ctDNA) assay to inform recurrence risk in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3602-3602.	0.8	12
76	Predictable early onset high-dose-glucocorticoid-associated-irAE and its predictive role in anti-PD-1 monotherapy treated advanced melanoma patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9544-9544.	0.8	2
77	Liquid biopsy using plasma proteomic profiling to reveal predictors of immunotherapy response.. <i>Journal of Clinical Oncology</i> , 2019, 37, 130-130.	0.8	1
78	Prognostic models for advanced melanoma patients treated with anti-PD-1 monotherapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 133-133.	0.8	0
79	Use of immunotherapy for stage-III and IV melanoma and likelihood of regional and distant lymph node resection and surgical resection for distant metastasis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9558-9558.	0.8	0
80	Organ site-specific radiological responses in anti-PD-1 monotherapy treated advanced melanoma patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9552-9552.	0.8	0
81	Co-targeting <sc>BET</sc> and <sc>MEK</sc> as salvage therapy for <sc>MAPK</sc> and checkpoint inhibitor-resistant melanoma. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	79
82	Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. <i>Clinical Cancer Research</i> , 2018, 24, 4771-4784.	3.2	29
83	Atypical ALK-positive Spitz tumors with 9p21 homozygous deletion: Report of two cases and review of the literature. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 136-140.	0.7	11
84	<i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. <i>Cancer Discovery</i> , 2018, 8, 196-215.	7.7	392
85	A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma. <i>Cancer Immunology Research</i> , 2018, 6, 79-86.	1.6	61
86	CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. <i>Cancer Discovery</i> , 2018, 8, 216-233.	7.7	503
87	A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. <i>Cell</i> , 2018, 175, 984-997.e24.	13.5	892
88	Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. <i>Cell</i> , 2018, 175, 998-1013.e20.	13.5	1,260
89	Toward Minimal Residual Disease-Directed Therapy in Melanoma. <i>Cell</i> , 2018, 174, 843-855.e19.	13.5	514
90	Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. <i>Nature Medicine</i> , 2018, 24, 1545-1549.	15.2	473

#	ARTICLE	IF	CITATIONS
91	Immune checkpoint inhibition (ICI) in advanced cutaneous squamous cell carcinoma (cSCC): Clinical response and correlative biomarker analysis.. Journal of Clinical Oncology, 2018, 36, 9564-9564.	0.8	7
92	The Role of Surgery for Melanoma in an Era of Effective Systemic Therapy. Current Oncology Reports, 2017, 19, 17.	1.8	30
93	Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response. Cancer Research, 2017, 77, 2318-2327.	0.4	235
94	Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nature Communications, 2017, 8, 1136.	5.8	686
95	PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature, 2017, 550, 133-136.	13.7	146
96	Lymphatic versus Hematogenous Melanoma Metastases: Support for Biological Heterogeneity without Clear Clinical Application. Journal of Investigative Dermatology, 2017, 137, 2466-2468.	0.3	1
97	Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence. Cell Reports, 2017, 21, 2796-2812.	2.9	77
98	Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. Oncotarget, 2017, 8, 25395-25417.	0.8	64
99	Clinical Observations and Molecular Variables of Primary Vascular Leiomyosarcoma. JAMA Surgery, 2016, 151, 347.	2.2	40
100	Metastatic melanoma with spontaneous complete regression of a thick primary lesion. JAAD Case Reports, 2016, 2, 439-441.	0.4	16
101	Principles of Melanoma Staging. Cancer Treatment and Research, 2016, 167, 131-148.	0.2	29
102	Melanoma: Advances in Targeted Therapy and Molecular Markers. Annals of Surgical Oncology, 2015, 22, 3451-3458.	0.7	15
103	The role of surgeons in building a personalized medicine program. Journal of Surgical Oncology, 2015, 111, 3-8.	0.8	5
104	Beyond BRAF V600 : Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma. Journal of Investigative Dermatology, 2015, 135, 508-515.	0.3	138
105	Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. Journal of Clinical Investigation, 2015, 125, 1459-1470.	3.9	106
106	Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget, 2015, 6, 20099-20110.	0.8	41
107	Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer. Cancer, 2013, 119, 1593-1601.	2.0	182
108	Sentinel Lymph Node Biopsy in Melanoma. Cancer Journal (Sudbury, Mass), 2012, 18, 185-191.	1.0	28